Stock Scorecard
Stock Summary for ATAI Life Sciences N.V. (ATAI) - $3.82 as of 11/19/2025 8:35:58 PM EST
Total Score
7 out of 30
Safety Score
29 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ATAI
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ATAI
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ATAI
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ATAI
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ATAI (29 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ATAI
Financial Details for ATAI
Company Overview |
|
|---|---|
| Ticker | ATAI |
| Company Name | ATAI Life Sciences N.V. |
| Country | USA |
| Description | ATAI Life Sciences BV is a pioneering biopharmaceutical company headquartered in Berlin, Germany, dedicated to transforming mental health care through the development of innovative psychedelic therapies. With a strong emphasis on addressing unmet medical needs, ATAI utilizes its proprietary technology platform to advance a diverse pipeline of treatments aimed at various mental health disorders. The company actively collaborates with prominent research institutions, positioning itself as a leader in the burgeoning psychedelics sector and emphasizing its commitment to scientific innovation and patient-centered solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 3.82 |
| Price 4 Years Ago | 7.63 |
| Last Day Price Updated | 11/19/2025 8:35:58 PM EST |
| Last Day Volume | 3,349,714 |
| Average Daily Volume | 6,547,309 |
| 52-Week High | 6.75 |
| 52-Week Low | 1.15 |
| Last Price to 52 Week Low | 232.17% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 42.93 |
| Sector PE | 115.35 |
| 5-Year Average PE | -3.89 |
| Free Cash Flow Ratio | 47.75 |
| Industry Free Cash Flow Ratio | 13.62 |
| Sector Free Cash Flow Ratio | 27.55 |
| Current Ratio Most Recent Quarter | 7.90 |
| Total Cash Per Share | 0.08 |
| Book Value Per Share Most Recent Quarter | 0.73 |
| Price to Book Ratio | 9.01 |
| Industry Price to Book Ratio | 33.51 |
| Sector Price to Book Ratio | 33.20 |
| Price to Sales Ratio Twelve Trailing Months | 472.94 |
| Industry Price to Sales Ratio Twelve Trailing Months | 28.80 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.69 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 363,191,000 |
| Market Capitalization | 1,387,389,620 |
| Institutional Ownership | 27.64% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -96.80% |
| Annual Earnings Growth | -271.09% |
| Reported EPS 12 Trailing Months | -0.83 |
| Reported EPS Past Year | -0.57 |
| Reported EPS Prior Year | -0.93 |
| Net Income Twelve Trailing Months | -154,192,000 |
| Net Income Past Year | -149,269,000 |
| Net Income Prior Year | -40,224,000 |
| Quarterly Revenue Growth YOY | 1,773.00% |
| 5-Year Revenue Growth | -75.27% |
| Operating Margin Twelve Trailing Months | -3,797.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 30,402,000 |
| Total Cash Past Year | 17,505,000 |
| Total Cash Prior Year | 45,034,000 |
| Net Cash Position Most Recent Quarter | 21,102,000 |
| Net Cash Position Past Year | 3,372,000 |
| Long Term Debt Past Year | 14,133,000 |
| Long Term Debt Prior Year | 17,877,000 |
| Total Debt Most Recent Quarter | 9,300,000 |
| Equity to Debt Ratio Past Year | 0.89 |
| Equity to Debt Ratio Most Recent Quarter | 0.94 |
| Total Stockholder Equity Past Year | 116,297,000 |
| Total Stockholder Equity Prior Year | 242,962,000 |
| Total Stockholder Equity Most Recent Quarter | 159,751,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -90,102,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.25 |
| Free Cash Flow Past Year | -82,532,000 |
| Free Cash Flow Prior Year | -84,708,000 |
Options |
|
| Put/Call Ratio | 0.10 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.38 |
| MACD Signal | -0.21 |
| 20-Day Bollinger Lower Band | 2.75 |
| 20-Day Bollinger Middle Band | 4.54 |
| 20-Day Bollinger Upper Band | 6.34 |
| Beta | 1.60 |
| RSI | 33.74 |
| 50-Day SMA | 2.84 |
| 150-Day SMA | 2.02 |
| 200-Day SMA | 2.54 |
System |
|
| Modified | 11/19/2025 5:54:57 PM EST |